Marshall Wace LLP Sells 2,016,626 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Marshall Wace LLP lowered its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 85.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 337,130 shares of the biopharmaceutical company's stock after selling 2,016,626 shares during the period. Marshall Wace LLP owned approximately 0.16% of Sangamo Therapeutics worth $344,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. EAM Investors LLC bought a new stake in Sangamo Therapeutics in the fourth quarter worth $256,000. Barclays PLC grew its position in Sangamo Therapeutics by 6,324,700.0% during the 4th quarter. Barclays PLC now owns 63,248 shares of the biopharmaceutical company's stock valued at $65,000 after purchasing an additional 63,247 shares during the last quarter. ExodusPoint Capital Management LP purchased a new stake in Sangamo Therapeutics during the 4th quarter valued at about $42,000. Geode Capital Management LLC increased its stake in Sangamo Therapeutics by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company's stock valued at $2,257,000 after purchasing an additional 73,540 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 21,793 shares in the last quarter. Hedge funds and other institutional investors own 56.93% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on SGMO. Truist Financial reduced their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $2.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $5.17.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock traded down $0.02 on Friday, reaching $0.70. The stock had a trading volume of 2,887,567 shares, compared to its average volume of 8,638,178. The stock has a market cap of $160.44 million, a P/E ratio of -0.93 and a beta of 1.46. Sangamo Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $3.18. The company has a 50 day simple moving average of $0.78 and a 200 day simple moving average of $1.36.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million. On average, equities research analysts anticipate that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.